Challenges to the Clinical Application of Pluripotent Stem Cells: Towards Genomic and Functional Stability

Overview

Journal Genome Med

Publisher Biomed Central

Specialty Genetics

Date 2012 Jun 30

PMID 22741526

Citations 18

Authors

Xuemei Fu

Yang Xu

Affiliations

Soon will be listed here.

Abstract

Human embryonic stem cells (hESCs) can undergo unlimited self-renewal and are pluripotent, retaining the ability to differentiate into all cell types in the body. As a renewable source of various types of human cells, hESCs hold great therapeutic potential. Although significant advances have been achieved in defining the conditions needed to differentiate hESCs into various types of biologically active cells, many challenges remain in the clinical development of hESC-based cell therapy, such as the immune rejection of allogeneic hESC-derived cells by recipients. Breakthroughs in the generation of induced pluripotent stem cells (iPSCs), which are reprogrammed from somatic cells with defined factors, raise the hope that autologous cells derived from patient-specific iPSCs can be transplanted without immune rejection. However, recent genomic studies have revealed epigenetic and genetic abnormalities associated with induced pluripotency, a risk of teratomas, and immunogenicity of some iPSC derivatives. These findings have raised safety concerns for iPSC-based therapy. Here, we review recent advances in understanding the genomic and functional stability of human pluripotent stem cells, current challenges to their clinical application and the progress that has been made to overcome these challenges.

Citing Articles

Stem Cell Therapy for Diseases of Livestock Animals: An In-Depth Review.

Narasimha R, Shreya S, Jayabal V, Yadav V, Rath P, Mishra B Vet Sci. 2025; 12(1).

PMID: 39852942 PMC: 11768649. DOI: 10.3390/vetsci12010067.

Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing.

Yin X, Li Q, Shu Y, Wang H, Thomas B, Maxwell J J Biomed Sci. 2024; 31(1):47.

PMID: 38724973 PMC: 11084032. DOI: 10.1186/s12929-024-01035-4.

New treatment methods for myocardial infarction.

Sun B, Wang L, Guo W, Chen S, Ma Y, Wang D Front Cardiovasc Med. 2023; 10:1251669.

PMID: 37840964 PMC: 10569499. DOI: 10.3389/fcvm.2023.1251669.

Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.

Dhanjal D, Singh R, Sharma V, Nepovimova E, Adam V, Kuca K Curr Med Chem. 2023; 31(13):1646-1690.

PMID: 37138422 DOI: 10.2174/0929867330666230503144619.

BNIP3-dependent mitophagy safeguards ESC genomic integrity via preventing oxidative stress-induced DNA damage and protecting homologous recombination.

Zhao Q, Liu K, Zhang L, Li Z, Wang L, Cao J Cell Death Dis. 2022; 13(11):976.

PMID: 36402748 PMC: 9675825. DOI: 10.1038/s41419-022-05413-4.

References

Ji J, Ng S, Sharma V, Neculai D, Hussein S, Sam M . Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells. 2011; 30(3):435-40. DOI: 10.1002/stem.1011. View

Anokye-Danso F, Trivedi C, Juhr D, Gupta M, Cui Z, Tian Y . Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011; 8(4):376-88. PMC: 3090650. DOI: 10.1016/j.stem.2011.03.001. View

DAmour K, Bang A, Eliazer S, Kelly O, Agulnick A, Smart N . Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006; 24(11):1392-401. DOI: 10.1038/nbt1259. View

Schwartz S, Hubschman J, Heilwell G, Franco-Cardenas V, Pan C, Ostrick R . Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. 2012; 379(9817):713-20. DOI: 10.1016/S0140-6736(12)60028-2. View

Mitjavila-Garcia M, Simonin C, Peschanski M . Embryonic stem cells: meeting the needs for cell therapy. Adv Drug Deliv Rev. 2005; 57(13):1935-43. DOI: 10.1016/j.addr.2005.06.001. View

Almstrup K, Hoei-Hansen C, Wirkner U, Blake J, Schwager C, Ansorge W . Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004; 64(14):4736-43. DOI: 10.1158/0008-5472.CAN-04-0679. View

Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W . Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 2008; 3(5):475-9. DOI: 10.1016/j.stem.2008.10.002. View

Pelengaris S, Khan M, Evan G . c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002; 2(10):764-76. DOI: 10.1038/nrc904. View

Fujikawa T, Oh S, Pi L, Hatch H, Shupe T, Petersen B . Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol. 2005; 166(6):1781-91. PMC: 1602425. DOI: 10.1016/S0002-9440(10)62488-1. View

10.

Melkoumian Z, Weber J, Weber D, Fadeev A, Zhou Y, Dolley-Sonneville P . Synthetic peptide-acrylate surfaces for long-term self-renewal and cardiomyocyte differentiation of human embryonic stem cells. Nat Biotechnol. 2010; 28(6):606-10. DOI: 10.1038/nbt.1629. View

11.

Suzuki H, Miyazono K . Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl). 2010; 88(11):1085-94. DOI: 10.1007/s00109-010-0650-1. View

12.

Viswanathan S, Daley G, Gregory R . Selective blockade of microRNA processing by Lin28. Science. 2008; 320(5872):97-100. PMC: 3368499. DOI: 10.1126/science.1154040. View

13.

Liu D, Xu Y . p53, oxidative stress, and aging. Antioxid Redox Signal. 2010; 15(6):1669-78. PMC: 3151427. DOI: 10.1089/ars.2010.3644. View

14.

Marion R, Strati K, Li H, Murga M, Blanco R, Ortega S . A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009; 460(7259):1149-53. PMC: 3624089. DOI: 10.1038/nature08287. View

15.

Coutts M, Keirstead H . Stem cells for the treatment of spinal cord injury. Exp Neurol. 2007; 209(2):368-77. DOI: 10.1016/j.expneurol.2007.09.002. View

16.

Crook J, Peura T, Kravets L, Bosman A, Buzzard J, Horne R . The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell. 2008; 1(5):490-4. DOI: 10.1016/j.stem.2007.10.004. View

17.

Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick J . Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011; 333(6039):218-21. DOI: 10.1126/science.1201219. View

18.

Lunn J, Sakowski S, Federici T, Glass J, Boulis N, Feldman E . Stem cell technology for the study and treatment of motor neuron diseases. Regen Med. 2011; 6(2):201-13. PMC: 3154698. DOI: 10.2217/rme.11.6. View

19.

Shi Y, Desponts C, Do J, Hahm H, Scholer H, Ding S . Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008; 3(5):568-74. DOI: 10.1016/j.stem.2008.10.004. View

20.

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View